Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny
The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.
The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.